568584-57-6

Basic information

• Product Name: Benzoic acid, 4-(4-amino-1-piperidinyl)-3-methoxy-, methyl ester
• CAS NO: 568584-57-6
• Molecular Formula: C14H20N2O3
• Molecular Weight: 264.324
• Mol File: 568584-57-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(4-amino-1-piperidinyl)-3-methoxy-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(4-amino-1-piperidinyl)-3-methoxy-, methyl ester(568584-57-6)
• EPA Substance Registry System: Benzoic acid, 4-(4-amino-1-piperidinyl)-3-methoxy-, methyl ester(568584-57-6)

Safety Data

• Hazardous Substances Data: 568584-57-6(Hazardous Substances Data)

Upstream product

• 3592-25-4 1,5-dichloropentan-3-one 
• 51446-31-2 4-fluoro-3-hydroxybenzoic acid 
• 41608-64-4 methyl 3-methoxy-4-aminobenzoate 
• 5081-37-8 methyl 3-methoxy-4-nitrobenzoate 
• 619-14-7 3-hydroxy-4-nitro-benzoic acid 
• 74385-37-8 methyl 4-fluoro-3-methoxy-benzoate 
• 247035-44-5 methyl 4-{4-(methanesulfonyloxy)piperidin-1-yl}-3-methoxybenzoate 
• 247035-42-3 methyl 4-(4-hydroxypiperidin-1-yl)-3-methoxybenzoate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 247035-43-4 4-(4-azido-piperidin-1-yl)-3-methoxy-benzoic acid methyl ester 

Downstream Products

• 247035-46-7 3-methoxy-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoic acid 
• 247034-74-8 (2S)-benzenesulfonylamino-3-[3-hydroxy-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionic acid 
• 247034-71-5 tert-butyl (2S)-benzenesulfonylamino-3-[3-methoxy-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 247035-45-6 methyl 3-methoxy-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate 

Relevant articles and documents

A scalable synthesis of MN-447, an antagonist for integrins αvβ3 and αIIbβ 3

(2S)-Benzeneslfonylamino-3-[3-methoxy-4-{4-(1,4,5,6-tetrahydropyrimidin-2- ylamino)piperidin-1-yl}benzoylamino]propionic acid, MN-447, is a potent antagonist of the integrins αvβ33 and αIIbβ3 Herein, we report a novel synthetic protocol that produces MN-447 in an overall yield of 45%. This protocol, when compared with the original synthetic route for MN-447, is more cost-effective, requires fewer steps, does not require chromatographic purification of intermediates and MN-447, and increases the overall yield by 35%. This report focuses on the synthetic strategies that were developed for this protocol. Now, the large quantities of MN-447 that are needed for preclinical and toxicological studies can be readily obtained.